Hyam (“Hy”) Levitsky previously served as Executive Vice President, Chief Scientific Officer of Juno Therapeutics from May 2015 through April 2018. Prior to joining Juno, Hy held the position of Head of Cancer Immunology at Roche Pharma. Prior to that, Hy served as a Professor of Oncology, Medicine and Urology at The Johns Hopkins University School of Medicine. Hy received a B.S. from the University of Pennsylvania School of Engineering and Applied Science and an M.D. from The Johns Hopkins School of Medicine. His areas of expertise include Oncology, Immunology, Hematologic Malignances / Bone Marrow Transplantation (serving as Scientific Director of the George Santos Bone Marrow Transplant Program), Cellular and Molecular Medicine, and Pathobiology. Hy is also a founding Executive Committee member of the Cancer Immunotherapy Consortium of the Cancer Research Institute. He was a founding member of MIATA (Minimal Information About T cell Assays), advises the FDA on cancer immunotherapy issues and serves on the External Scientific Advisory Board of the Pasteur Institute’s Center for Human Immunology.